


Venue of the meeting



Aula Magna
Azienda Ospedaliero-Universitaria
Arcispedale "S. Anna"
Via Aldo Moro, 8 - 44124 Cona (FE) - Italy
www.ospfe.it

Registration

The participation to the event is FREE but the REGISTRATION IS MANDATORY by using the online registration form at www.cieffeerre.it/translational_medicine
Deadline for the registration **the 24th of October 2016**

Continuing Medical Education (CME)

This is a CME event accredited for 100 PARTICIPANTS (graduated in Medicine and Surgery)
Disciplines: PULMONOLOGY, ALLERGOLOGY AND CLINICAL IMMUNOLOGY, GERIATRICS, INTERNAL MEDICINE, OCCUPATIONAL MEDICINE, GENERAL PRACTITIONERS [FAMILY (PRIMARY CARE) DOCTORS].
CME Credits assigned: 8
To obtain the CME credits is mandatory to participate to the entire duration of the event (8 hours), to sign the CME register (at the beginning and at the end of the meeting) and to pass the final evaluation questionnaire.

CME Provider



Euromediform srl
Via A. Cesalpino 5/B
50134 Firenze, Italy
Tel. +39 055.7954222
Fax +39 055.7954260
info@euromediform.it

Organising Secretariat



Consorzio Futuro in Ricerca
Ufficio Convegni e Attività Formative
Via Saragat 1 Blocco B 1° Piano
44122 Ferrara, Italy
Tel. +39 0532.762404
Fax +39 0532.767347
convegni@unife.it
www.cieffeerre.it

This event has been realised with the kind contribution of unrestricted educational grants by:



TRANSLATIONAL MEDICINE AND THE PULMONOLOGIST

Saturday the 29th of October 2016

Aula Magna Azienda Ospedaliero-Universitaria
"Arcispedale Sant'Anna"



Endorsed by

Università degli Studi di Ferrara
Azienda Ospedaliero-Universitaria Arcispedale Sant'Anna
Ordine dei Medici-Chirurghi e degli Odontoiatri della Provincia di Ferrara

Good studies of translational medicine are mandatory to reach a better understanding, at the molecular level, of the pathogenesis of lung diseases. We still have a significant unmet needs in the pathogenesis and pharmacological personalised treatment of difficult-to-control asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), idiopathic pulmonary fibrosis (IPF) and idiopathic pulmonary arterial hypertension (IPAH). Collectively these lung diseases represent a major cause of morbidity and/or mortality worldwide. In addition there are molecular links, still largely under investigated, between COPD, lung, cancer and IPF all smoking-related disease but with different clinical-pathological expressions. It is particularly relevant that in a large longitudinal study of asymptomatic patients with mild-to-moderate COPD, 33% of subjects died of lung cancer over 15 years suggesting that lung cancer is a leading cause of morbidity and mortality in COPD patients. These patients share a common environmental risk factor (smoking) and a genetic predisposition represented by the incidence of these diseases in only a fraction of smokers. COPD is also a major independent risk factor for lung carcinoma, among smokers. Sepsis is a major cause of ARDS and this deadly disease can be considered another orphan disease due to the paucity of studies on its pathogenesis. IPAH is an uncommon lethal disease and we need to develop better drugs to modify its natural history.

For all these reasons the aim of this meeting is to gather together Italian and International experts in the field of these lung diseases to discuss in depth the cutting edge translational medicine research performed in these different diseases and to coordinate global research network efforts to promote a better knowledge in their pathogenesis and to obtain new targets for rationale drug development.

Scientific Organiser

Prof. Gaetano Caramori MD, PhD

Dipartimento di Scienze Mediche, Sezione di Medicina Interna e Cardiorespiratoria
Centro Interdipartimentale per lo Studio delle Malattie Infiammatorie delle Vie Aeree e Patologie Fumo-Correlate (CEMICEF), Università di Ferrara, Italy

Chairs and Speakers

Ian Adcock | Airways Disease Section, National Heart and Lung Institute, Imperial College London, London, UK

Bruno Balbi | Divisione di Pneumologia Riabilitativa, Fondazione Salvatore Maugeri, Pavia, Italy

Adam Barczyk | Katedra i Klinika Pneumologii, Slaski Uniwersytet Medyczny w Katowicach, Katowice, Poland

Gaetano Caramori | CEMICEF, Sezione di Medicina Interna e Cardiorespiratoria, Università di Ferrara, Italy

Gian Luca Casoni | UO di Pneumologia, Azienda Ospedaliero-Universitaria Arcispedale S. Anna, Ferrara, Italy

Adalberto Ciaccia | CEMICEF, Ferrara, Italy

Kian Fan Chung | Airways Disease Section, National Heart and Lung Institute, Imperial College London, London, UK

Marco Contoli | CEMICEF, Sezione di Medicina Interna e Cardiorespiratoria, Università di Ferrara, Italy

Antonino Di Stefano | Divisione di Pneumologia e Laboratorio di Citoimmunopatologia dell'Apparato Cardio Respiratorio, Fondazione Salvatore Maugeri, IRCCS, Veruno (NO) e Tradate (PV), Italy

Leonardo M. Fabbri | Department of Metabolic Medicine, University of Modena & Reggio Emilia, Sant'Agostino Estense Hospital, Italy

Giovanni Ferrara | Department of Respiratory Medicine and Allergy Karolinska University Hospital Solna, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

Trevor Hansel | Medical Director of the Imperial Clinical Respiratory Research Unit (ICRRU) at St Mary's Hospital, Faculty of Medicine at the National Heart and Lung Institute, Imperial College London, London, UK

Marc Humbert | Université Paris-Sud, Faculté de Médecine, Le Kremlin Bicêtre, France AP-HP, Centre de Référence de l'Hypertension Pulmonaire Sévère, Département Hospitalo-Universitaire (DHU) Thorax Innovation (TORINO), Service de Pneumologie, Hôpital de Bicêtre, Le Kremlin Bicêtre, France UMR_S999, Université Paris-Sud, INSERM, Laboratoire d'Excellence (LabEx) en Recherche sur le Médicament et l'Innovation Thérapeutique (LERMIT), Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France

Paul Kirkham | Airways Disease Section, University of Wolverhampton, UK

Alberto Papi | CEMICEF, Sezione di Medicina Interna e Cardiorespiratoria, Università di Ferrara, Italy

Fabio Luigi Massimo Ricciardolo | Facoltà di Medicina e Chirurgia San Luigi, Dipartimento di Scienze Cliniche e Biologiche, Clinica di Malattie dell'Apparato Respiratorio, Università di Torino, Italy

Aldo Pinto | Dipartimento di Farmacia/DIFARMA, Università di Salerno, Italy

Elizabeth Renzoni | Consultant Respiratory Physician at Royal Brompton Hospital and Honorary Senior Lecturer, Imperial College London, London, UK

Rosalinda Sorrentino | Dipartimento di Farmacia/DIFARMA, Università di Salerno, Italy

Savino Spadaro | Sezione di Ortopedia, Ostetricia e Ginecologia e Anestesiologia e Rianimazione, Università di Ferrara, Italy

Carlo Alberto Volta | Sezione di Ortopedia, Ostetricia e Ginecologia e Anestesiologia e Rianimazione, Università di Ferrara, Italy

Stephen Wort | Faculty of Medicine, National Heart and Lung Institute, Imperial College London, London, UK

- 08.00-08.30** Registration of the Participants
- 08.30-08.45** Opening of the meeting by the Honorary President (*Adalberto Ciaccia*)
- 08.45-09.00** Introduction of the meeting by the Rector of the University of Ferrara (*Giorgio Zauli*)

FIRST SESSION: DIFFICULT-TO-CONTROL ASTHMA

Chairs: Alberto Papi, Fabio L. M. Ricciardolo

- 09.00-09.30** Current personalised treatment of difficult-to-control asthma and new drugs under development (*Kian Fan Chung*)
- 09.30-10.00** Animal models of severe persistent asthma (*Ian Adcock*)
- 10.00-10.30** Experimental infection of asthmatic Patients with rhinovirus (*Marco Contoli*)
- 10.30-11.00** EU-funded BIOPRED project results (*Ian Adcock*)

SECOND SESSION: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND LUNG CANCER

Chairs: Bruno Balbi, Aldo Pinto

- 11.00-11.30** Current personalised treatment of stable COPD and new drugs under development (*Gaetano Caramori*)
- 11.30-12.00** Molecular pathogenesis of COPD: central vs peripheral lung (*Antonino Di Stefano*)
- 12.00-12.30** Animal models of lung cancer (*Rosalinda Sorrentino*)
- 12.30-13.00** Biomarkers of COPD (*Paul Kirkham*)
- 13.00-13.30** Molecular links between COPD and lung cancer (*Adam Barczyk*)

INVITED LECTURE

- 13.30-14.00** How to build a successful career in Academic Respiratory Medicine (*Leonardo M. Fabbri*)
- 14.00-15.00** Light lunch

THIRD SESSION: RESPIRATORY INFECTIONS AND ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)

Chairs: Carlo Alberto Volta, Stephen Wort

- 15.00-15.30** Airway defences against infections (*Trevor Hansel*)
- 15.30-16.00** Novel advances in the molecular pathogenesis of ARDS (*Savino Spadaro*)

FOURTH SESSION: IDIOPATHIC PULMONARY FIBROSIS (IPF) AND IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION (IPAH)

Chairs: Marc Humbert, Elizabeth Renzoni

- 16.00-16.30** Current personalised treatment of IPAH and new drugs under development (*Marc Humbert*)
- 16.30-17.00** Molecular pathogenesis of IPAH (*Stephen Wort*)
- 17.00-17.30** Current personalised treatment of stable IPF and new drugs under development (*Gian Luca Casoni*)
- 17.30-18.00** Molecular pathogenesis of IPF (*Giovanni Ferrara*)
- 18.00-18.15** CME questionnaire compilation and conclusions